Omnicell Inc (OMCL)

$45.69

+1.58

(+3.58%)▲

Market is closed - opens 8 PM, 25 Nov 2024

Performance

  • $43.48
    $45.73
    $45.69
    downward going graph

    4.84%

    Downside

    Day's Volatility :4.91%

    Upside

    0.08%

    downward going graph
  • $25.12
    $55.75
    $45.69
    downward going graph

    45.02%

    Downside

    52 Weeks Volatility :54.94%

    Upside

    18.04%

    downward going graph

Returns

PeriodOmnicell IncSector (Health Care)Index (Russel 2000)
3 Months
1.99%
-7.3%
0.0%
6 Months
44.13%
-0.5%
0.0%
1 Year
35.3%
10.5%
0.0%
3 Years
-75.12%
8.8%
-24.0%

Highlights

Market Capitalization
2.0B
Book Value
$26.59
Earnings Per Share (EPS)
-0.39
PEG Ratio
2.28
Wall Street Target Price
56.5
Profit Margin
-1.66%
Operating Margin TTM
2.54%
Return On Assets TTM
-0.87%
Return On Equity TTM
-1.46%
Revenue TTM
1.1B
Revenue Per Share TTM
23.22
Quarterly Revenue Growth YOY
-5.4%
Gross Profit TTM
596.7M
EBITDA
26.5M
Diluted Eps TTM
-0.39
Quarterly Earnings Growth YOY
0.56
EPS Estimate Current Year
1.69
EPS Estimate Next Year
1.81
EPS Estimate Current Quarter
0.4
EPS Estimate Next Quarter
0.47

Analyst Recommendation

Buy
    60%Buy
    33%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Omnicell Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
5
5
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 23.66%

Current $45.69
Target $56.50

Company Financials

FY18Y/Y Change
Revenue
787.3M
↑ 9.93%
Net Income
37.7M
↑ 83.11%
Net Profit Margin
4.79%
↑ 1.91%
FY19Y/Y Change
Revenue
897.0M
↑ 13.94%
Net Income
61.3M
↑ 62.58%
Net Profit Margin
6.84%
↑ 2.05%
FY20Y/Y Change
Revenue
892.2M
↓ 0.54%
Net Income
32.2M
↓ 47.51%
Net Profit Margin
3.61%
↓ 3.23%
FY21Y/Y Change
Revenue
1.1B
↑ 26.88%
Net Income
77.8M
↑ 141.81%
Net Profit Margin
6.88%
↑ 3.27%
FY22Y/Y Change
Revenue
1.3B
↑ 14.48%
Net Income
5.6M
↓ 92.74%
Net Profit Margin
0.44%
↓ 6.44%
FY23Y/Y Change
Revenue
1.1B
↓ 11.48%
Net Income
-20.4M
↓ 460.68%
Net Profit Margin
-1.78%
↓ 2.22%
Q2 FY23Q/Q Change
Revenue
299.0M
↑ 2.87%
Net Income
3.5M
↓ 123.01%
Net Profit Margin
1.15%
↑ 6.31%
Q3 FY23Q/Q Change
Revenue
298.7M
↓ 0.1%
Net Income
5.6M
↑ 60.91%
Net Profit Margin
1.86%
↑ 0.71%
Q4 FY23Q/Q Change
Revenue
258.8M
↓ 13.33%
Net Income
-14.4M
↓ 358.87%
Net Profit Margin
-5.55%
↓ 7.41%
Q1 FY24Q/Q Change
Revenue
246.2M
↓ 4.9%
Net Income
-15.7M
↑ 9.05%
Net Profit Margin
-6.37%
↓ 0.82%
Q2 FY24Q/Q Change
Revenue
276.8M
↑ 12.45%
Net Income
3.7M
↓ 123.83%
Net Profit Margin
1.35%
↑ 7.72%
Q3 FY24Q/Q Change
Revenue
282.4M
↑ 2.03%
Net Income
8.6M
↑ 131.06%
Net Profit Margin
3.06%
↑ 1.71%
FY18Y/Y Change
Total Assets
1.1B
↑ 10.3%
Total Liabilities
401.6M
↓ 13.28%
FY19Y/Y Change
Total Assets
1.2B
↑ 14.76%
Total Liabilities
395.6M
↓ 1.51%
FY20Y/Y Change
Total Assets
1.8B
↑ 47.04%
Total Liabilities
857.0M
↑ 116.66%
FY21Y/Y Change
Total Assets
2.1B
↑ 17.43%
Total Liabilities
995.8M
↑ 16.2%
FY22Y/Y Change
Total Assets
2.2B
↑ 3.19%
Total Liabilities
1.1B
↑ 8.52%
FY23Y/Y Change
Total Assets
2.2B
↑ 0.73%
Total Liabilities
1.0B
↓ 3.95%
Q2 FY23Q/Q Change
Total Assets
2.2B
↓ 2.53%
Total Liabilities
1.0B
↓ 7.04%
Q3 FY23Q/Q Change
Total Assets
2.2B
↑ 1.26%
Total Liabilities
1.0B
↑ 0.37%
Q4 FY23Q/Q Change
Total Assets
2.2B
↑ 0.24%
Total Liabilities
1.0B
↑ 0.37%
Q1 FY24Q/Q Change
Total Assets
2.3B
↑ 2.55%
Total Liabilities
1.1B
↑ 5.51%
Q2 FY24Q/Q Change
Total Assets
2.3B
↑ 0.35%
Total Liabilities
1.1B
↓ 0.58%
Q3 FY24Q/Q Change
Total Assets
2.3B
↑ 0.52%
Total Liabilities
1.1B
↓ 1.52%
FY18Y/Y Change
Operating Cash Flow
104.0M
↑ 318.64%
Investing Cash Flow
-54.4M
↑ 55.41%
Financing Cash Flow
-13.6M
↑ 37.66%
FY19Y/Y Change
Operating Cash Flow
145.0M
↑ 39.48%
Investing Cash Flow
-61.7M
↑ 13.41%
Financing Cash Flow
-23.5M
↑ 72.68%
FY20Y/Y Change
Operating Cash Flow
185.9M
↑ 28.18%
Investing Cash Flow
-279.9M
↑ 353.86%
Financing Cash Flow
456.3M
↓ 2043.31%
FY21Y/Y Change
Operating Cash Flow
231.8M
↑ 24.72%
Investing Cash Flow
-412.5M
↑ 47.39%
Financing Cash Flow
47.4M
↓ 89.62%
FY22Y/Y Change
Operating Cash Flow
77.8M
↓ 66.45%
Investing Cash Flow
-58.7M
↓ 85.78%
Financing Cash Flow
-21.0M
↓ 144.24%
Q2 FY23Q/Q Change
Operating Cash Flow
72.9M
↑ 470.89%
Investing Cash Flow
-14.8M
↑ 8.63%
Financing Cash Flow
3.6M
↓ 6.71%

Technicals Summary

Sell

Neutral

Buy

Omnicell Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Omnicell Inc
Omnicell Inc
7.32%
44.13%
35.3%
-75.12%
-43.66%
Doximity, Inc.
Doximity, Inc.
16.37%
75.85%
96.25%
-15.59%
-9.06%
Solventum Corp
Solventum Corp
-2.33%
18.15%
2.47%
2.47%
2.47%
Veeva Systems Inc.
Veeva Systems Inc.
-1.47%
5.87%
22.66%
-24.91%
37.99%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-7.67%
3.92%
11.84%
36.29%
36.29%
Healthequity Inc
Healthequity Inc
18.99%
30.57%
52.21%
65.0%
63.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Omnicell Inc
Omnicell Inc
470.14
NA
2.28
1.69
-0.01
-0.01
NA
26.59
Doximity, Inc.
Doximity, Inc.
55.17
55.17
2.42
0.9
0.19
0.12
NA
5.15
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
57.21
57.21
1.21
4.76
0.13
0.06
NA
32.04
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
22.47
22.47
2.05
4.28
0.22
0.06
0.0
18.2
Healthequity Inc
Healthequity Inc
87.21
87.21
1.14
2.19
0.05
0.03
NA
24.7
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Omnicell Inc
Omnicell Inc
Buy
$2.0B
-43.66%
470.14
-1.66%
Doximity, Inc.
Doximity, Inc.
Hold
$9.0B
-9.06%
55.17
33.69%
Solventum Corp
Solventum Corp
Hold
$10.8B
2.47%
NA
15.73%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$34.7B
37.99%
57.21
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$37.5B
36.29%
22.47
8.56%
Healthequity Inc
Healthequity Inc
Buy
$9.1B
63.71%
87.21
9.61%

Insights on Omnicell Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 246.15M → 282.42M (in $), with an average increase of 6.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -15.67M → 8.63M (in $), with an average increase of 288.2% per quarter

  • Vs DOCS

    In the last 1 year, Doximity, Inc. has given 96.6% return, outperforming this stock by 60.7%

  • Vs HQY

    In the last 3 years, Omnicell Inc has experienced a drawdown of -75.1%, however Healthequity Inc resisted the overall trend and outperformed by 59.5%

Institutional Holdings

  • BlackRock Inc

    17.67%

  • Vanguard Group Inc

    11.95%

  • State Street Corp

    4.83%

  • Pacer Advisors, INC.

    4.47%

  • Morgan Stanley - Brokerage Accounts

    3.79%

  • Champlain Investment Partners, LLC

    3.34%

Company Information

since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice

Organization
Omnicell Inc
Employees
3660
CEO
Mr. Randall A. Lipps
Industry
Technology Services

FAQs